Financial Performance - Net revenue for the three months ended December 31, 2024, was 240.3million,adecreaseof14.1279.9 million for the same period in 2023[19]. - Gross profit for the six months ended December 31, 2024, was 351.6million,down16.0418.8 million in the prior year[19]. - The company reported a net loss of 85.2millionforthethreemonthsendedDecember31,2024,comparedtoanetincomeof52.9 million in the same period of 2023[19]. - Total net revenue for the three months ended December 31, 2024, was 240.3million,adecreaseof14.1279.9 million in 2023; for the six months, revenue was 488.4million,down11548.9 million[113]. - Non-GAAP Adjusted EBITDA for the three months ended December 31, 2024, was 50.1million,downfrom96.4 million in 2023; for the six months, it decreased from 189.7millionto112.5 million[118]. Assets and Liabilities - Total assets decreased from 3,401,449thousandasofJune30,2024,to3,142,375 thousand as of December 31, 2024, representing a decline of approximately 7.6%[17]. - Total liabilities decreased slightly from 1,439,218thousandto1,424,484 thousand, a decrease of about 1.0%[17]. - Stockholders' equity decreased from 1,962,231thousandto1,717,891 thousand, a decline of approximately 12.4%[17]. - Cash and cash equivalents decreased from 125,146thousandto85,850 thousand, a reduction of about 31.5%[17]. - The net carrying value of intangible assets decreased from 269.3millionasofJune30,2024,to250.1 million as of December 31, 2024[68]. Revenue and Expenses - Operating expenses increased significantly to 264.0millionforthethreemonthsendedDecember31,2024,comparedto151.0 million in the same period of 2023, representing a 74.3% increase[19]. - The company reported a significant increase in selling, general, and administrative expenses, which rose to 253.8millionforthethreemonthsendedDecember31,2024,comparedto137.7 million in the same period of 2023[19]. - Research and development expenses were relatively stable, totaling 726,000forthethreemonthsendedDecember31,2024,comparedto928,000 in the same period of 2023[19]. - Stock-based compensation expense for the six months ended December 31, 2024, was 9,519thousand,downfrom15,070 thousand in 2023[26]. - Stock-based compensation expense for the three months ended December 31, 2024, was 2.6million,downfrom8.4 million in the same period of 2023[94]. Cash Flow and Financing - The company reported a net cash provided by operating activities of 179,315thousandforthesixmonthsendedDecember31,2024,comparedto35,380 thousand in 2023[26]. - The Company had 100.0millioninoutstandingborrowingsundertheCreditFacilityatDecember31,2024,withaweightedaverageinterestrateof5.938189,754 thousand during the financing activities[26]. - The Company announced a share repurchase authorization of up to 1.0billion,withaninitialagreementtorepurchase400.0 million of its Common Stock[84]. - During the quarter ended December 31, 2024, the Company repurchased 6.3 million shares at an average price of 21.35pershare,totaling134.1 million[86]. Discontinued Operations - The company incurred a loss on disposal of its direct sourcing subsidiary, S2S Global, amounting to 51.7million,recordedwithinnetincomefromdiscontinuedoperations[31].−ThenetrevenuefromdiscontinuedoperationsforthethreemonthsendedDecember31,2024,was0, compared to 54.874millionforthesameperiodin2023[40].−Thecompanyreportedanetlossfromdiscontinuedoperations,netoftax,attributabletostockholdersof39.389 million for the three months ended December 31, 2024[40]. - The company recognized a gross profit of 7.402millionfromdiscontinuedoperationsforthethreemonthsendedDecember31,2024[40].−ThecompanyrecordedalossondisposalofS2SGlobalamountingto51.7 million during the three months ended December 31, 2024[39]. Future Outlook and Strategy - The company is focusing on maintaining and adding new GPO members, which is critical for revenue generation from administrative fees[11]. - Future growth may be impacted by competition and the consolidation in the healthcare industry, which could limit market share expansion[11]. - The company is exploring new product offerings and the integration of artificial intelligence to enhance service delivery and operational efficiency[11]. - The estimated amortization expense for the next five fiscal years totals 250.1million,with19.0 million estimated for fiscal year 2025[70]. - The Company sold its non-healthcare GPO member agreements to OMNIA for a total purchase price of 723.8million,allofwhichhasbeenreceivedasofDecember31,2024[78].Taxation−IncometaxbenefitforthethreemonthsendedDecember31,2024,was18.0 million, compared to an expense of 18.3millionforthesameperiodin2023,reflectingeffectivetaxratesof284.7 million, significantly lower than $32.1 million for the same period in 2023, with effective tax rates of 15% and 26% respectively[104]. Risk Management - The company does not expect changes in interest rates to have a material impact on its results of operations or financial position[261]. - The company plans to mitigate default, market, and investment risks by investing in low-risk securities[261]. - The company does not hold any material derivative financial instruments[261]. - The company is not currently involved in any material litigation, but may face regulatory inquiries or investigations that could adversely affect its business[109].